ClinicalTrials.gg
Not yet recruitingNCT07948902DRSB_LRPUpdated Nov 19, 2026

Deep Rectus Sheath Block for Postoperative Pain in Laparoscopic Radical Prostatectomy

An interventional study of Ultrasound-guided bilateral deep rectus sheath block and Sham deep rectus sheath block in Pain, Postoperative, Prostate Cancer and Prostatectomy, sponsored by Marmara University Pendik Training and Research Hospital. Not yet recruiting at 1 site in Turkey (Türkiye). Open to male participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Marmara University Pendik Training and Research Hospital · Not applicable, Interventional, and Supportive care

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 1,106 studies in Pain, Postoperative with a site in Turkey — 267 open to participants now, 301 under way, none of them phase 3. Pain, Postoperative · Turkey.

Planned enrollment
387th of 891
74 · median 70
Started
2026
with 227 others
No phase
822 of 1,106
221 open now
Primary completion
2027-04
later than 238 of 300 live
Registered
1,106th of 1,106
by date

Among the 1,106 studies in Pain, Postoperative with a site in Turkey, this one is the 387th largest by planned enrollment of the 891 interventional ones that give a count, is one of 228 that started in 2026, is one of 822 with no phase, reaches primary completion later than 238 of the 300 other live ones, and was the 1,106th registered.

Pain, Postoperative

5,671 studies on the registry are indexed under Pain, Postoperative; 1,241 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

267 of the 1,106 studies in Pain, Postoperative with a site in Turkey are open now. Recruiting first, the newest first:

262 more — sign in →

All 267 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 677 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years to 75 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,106 studies in Pain, Postoperative with a site in Turkey, or all of them as a file.
02

Study summary

This study aims to find out whether an ultrasound-guided deep rectus sheath block, a regional anesthesia technique that numbs the nerves of the front abdominal wall, reduces pain and the need for opioid pain medication after laparoscopic radical prostatectomy. Adult men scheduled for elective laparoscopic radical prostatectomy will be randomly assigned to receive either a bilateral deep rectus sheath block with the local anesthetic bupivacaine or a sham (placebo) block with saline, performed after induction of general anesthesia. Patients and the clinicians caring for and assessing them will not know which treatment was given. All patients will receive the same general anesthesia and the same pain-relief protocol, including intravenous tramadol by patient-controlled analgesia (PCA). The main question is whether the block reduces the amount of tramadol used in the first 24 hours after surgery. Pain scores, rescue pain medication, opioid-related side effects and quality of recovery will also be compared.

Read the detailed description

Background: Laparoscopic radical prostatectomy (LRP) causes less pain than open surgery, but many patients still experience moderate-to-severe pain on the first postoperative day, largely originating from the infraumbilical midline extraction incision. The 2021 PROSPECT/ESRA recommendations state that evidence for alternative fascial plane blocks such as the rectus sheath block in this population is insufficient and that high-quality controlled trials are needed. The deep rectus sheath block (deep RSB), described by Fusco et al. in 2024, deposits local anesthetic deep to the posterior rectus sheath and is intended to provide wider coverage of the anterior cutaneous branches of the T7-T12 thoracoabdominal nerves and the infraumbilical midline incision. To our knowledge, no sham-controlled randomized trial of deep RSB in LRP has been published.

Design: Single-center, prospective, randomized, sham-controlled, double-blind, parallel-group trial at Marmara University Pendik Training and Research Hospital, Istanbul, Türkiye.

Randomization and allocation concealment: Before the start of the study, a researcher not involved in data collection will prepare a computer-generated simple randomization list (www.randomizer.org) with a 1:1 allocation ratio. Allocation will be concealed using sequentially numbered, opaque, sealed envelopes, opened after induction of general anesthesia by an anesthesiologist not otherwise involved in the study, who will prepare the study solution in identical syringes.

Anesthesia: All patients receive standardized general anesthesia (lidocaine, propofol, remifentanil, rocuronium for induction; sevoflurane and remifentanil infusion for maintenance). Thirty minutes before the end of surgery all patients receive IV paracetamol 1 g, tramadol 1 mg/kg and dexketoprofen 50 mg. PONV prophylaxis consists of dexamethasone 4 mg at induction and ondansetron 4 mg before the end of surgery.

Intervention: After induction and before skin incision, with the patient supine, a high-frequency linear ultrasound probe is placed transversely just lateral to the umbilicus. A 22-G, 80- or 100-mm block needle is advanced in-plane through the posterior rectus sheath into the fascial plane immediately deep to it. After confirmation by hydrodissection with 1-2 mL saline, 20 mL of study solution is injected on each side (40 mL total): 0.375% bupivacaine in Group DRSB or 0.9% saline in Group P. All blocks are performed by a single anesthesiologist experienced in deep RSB.

Postoperative analgesia: IV tramadol PCA (10 mg bolus, 10-minute lockout, no background infusion). IV morphine 3 mg is given as rescue analgesia when NRS ≥4, repeated every 20 minutes until NRS \<4.

Sample size: Based on a pilot series of 10 deep RSB patients (24-h tramadol 36.8 ± 24.8 mg) and published no-block data (102.17 ± 91.93 mg tramadol-equivalent), the expected difference is 65.37 mg (pooled SD 81.2 mg; Cohen's d 0.80). With two-sided α = 0.05 and 90% power, 34 patients per group are required; allowing 10% dropout, 37 per group (74 in total) will be enrolled.

Statistical analysis: Normality will be assessed with the Shapiro-Wilk test. The primary outcome will be compared with Student's t-test or the Mann-Whitney U test, as appropriate. Repeated measures (NRS over time) will be analyzed with a mixed model; categorical variables with the chi-square or Fisher's exact test. Bonferroni correction will be applied for multiple comparisons. Analyses will follow both the intention-to-treat and per-protocol principles.

03

Conditions studied

  • Pain, Postoperative
  • Prostate Cancer
  • Prostatectomy

Keywords

  • deep rectus sheath block
  • rectus sheat block
  • fascial plane block
  • regional anesthesia
  • laparoscopic radical prostatectomy
  • opioid consumption
  • patient-controlled analgesia
  • tramadol
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male patients aged 18-75 years
  • (ASA) physical status I-III
  • Scheduled for elective laparoscopic radical prostatectomy
  • Written

Exclusion criteria

Exclusion Criteria:

  • Known allergy to local anesthetics or opioids
  • Coagulopathy or ongoing anticoagulant/antiplatelet therapy
  • Active infection or skin pathology at the block site
  • Severe hepatic or renal failure
  • Chronic opioid use (≥3 months)
  • Intraoperative conversion to open surgery (withdrawal after randomization)
  • Withdrawal of consent or loss of follow-up data
  • Body weight \<60 kg (to keep the total bupivacaine dose of 150 mg within the maximum recommended dose of 2.5 mg/kg)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
74 participants (estimated)

Study arms

  • Experimental
    Group DRSB (Deep Rectus Sheath Block)

    Bilateral ultrasound-guided deep rectus sheath block with 20 mL of 0.375% bupivacaine per side (40 mL total), performed after induction of general anesthesia and before skin incision, in addition to standardized general anesthesia, multimodal analgesia and IV tramadol PCA.

    Procedure: Ultrasound-guided bilateral deep rectus sheath block

  • Sham comparator
    Group S (Sham Block)

    Bilateral ultrasound-guided sham deep rectus sheath block with 20 mL of 0.9% saline per side (40 mL total), using an identical technique and timing, in addition to standardized general anesthesia, multimodal analgesia, and IV tramadol PCA.

    Procedure: Sham deep rectus sheath block

Interventions

  • ProcedureUltrasound-guided bilateral deep rectus sheath block

    Under ultrasound guidance (linear probe placed transversely lateral to the umbilicus), a 22-G needle is advanced in-plane through the posterior rectus sheath into the plane immediately deep to it; after hydrodissection, 20 mL of 0.375% bupivacaine is injected on each side.

  • ProcedureSham deep rectus sheath block

    Identical ultrasound-guided technique, with 20 mL of 0.9% saline injected on each side.

06

What researchers measure

Primary outcomes

  1. Cumulative 24-hour intravenous tramadol consumption via patient-controlled analgesia

    Total amount (mg) of IV tramadol delivered by the PCA device (10 mg bolus, 10-minute lockout, no background infusion), recorded from the PCA device log.

    Time frame: From arrival in the recovery unit (postoperative hour 0) to postoperative hour 24

Secondary outcomes

  1. Postoperative pain scores (Numeric Rating Scale)

    Pain intensity at rest assessed with the 11-point Numeric Rating Scale (0 = no pain, 10 = worst pain imaginable); higher scores indicate worse pain.

    Time frame: Postoperative hours 0, 2, 6, 12 and 24

  2. Quality of Recovery (QoR-15)

    Validated Turkish version of the Quality of Recovery-15 questionnaire; total score 0-150, higher scores indicate better quality of recovery.

    Time frame: Preoperatively (baseline) and at postoperative hour 24

  3. Intraoperative remifentanil consumption

    Mean remifentanil infusion rate (µg/kg/min) during maintenance of anesthesia, titrated to hemodynamic response.

    Time frame: From induction of anesthesia to the end of surgery

  4. Total rescue morphine consumption

    Total amount (mg) of IV morphine given as rescue analgesia (3 mg when NRS ≥4, repeated every 30 minutes until NRS \<4).

    Time frame: 0-24 hours postoperatively

  5. Incidence of postoperative nausea and vomiting

    Number of participants with nausea and/or vomiting.

    Time frame: 0-24 hours postoperatively

  6. Incidence of pruritus

    Number of participants with pruritus.

    Time frame: 0-24 hours postoperatively

  7. Incidence of excessive sedation

    Number of participants with excessive sedation, defined as a Pasero Opioid-Induced Sedation Scale (POSS) score ≥3.

    Time frame: 0-24 hours postoperatively

  8. Incidence of hypotension

    Number of participants with hypotension, defined as mean arterial pressure \<65 mmHg.

    Time frame: 0-24 hours postoperatively

  9. Incidence of respiratory depression

    Number of participants with respiratory depression, defined as a respiratory rate \<8 breaths/min and/or peripheral oxygen saturation (SpO₂) \<90%.

    Time frame: 0-24 hours postoperatively

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared because the informed consent and ethics approval restrict use of the collected data to this study. Aggregated results will be published.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Apr 2027, 5 months later.

Of 2,106 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 5 months is below that.

Counting every sponsor, half of 2,119 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2026
First posted
Nov 19, 2026
StartEst.
Nov 16, 2026
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07948902
Lead sponsor
Marmara University Pendik Training and Research Hospital
Responsible party
betül yüsra şirin (Specialist, Marmara University Pendik Training and Research Hospital) — Principal investigator
First posted
Nov 19, 2026
Start date
Nov 16, 2026 (estimated)
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Betul Y Sirin, MD
Contact
yusrasirin@gmail.com
+90 216 657 06 06
Beliz Bilgili, Prof. Dr.
principal investigator · Marmara University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion